Abstract
..
Main
..
Feedback
Home
c19early.org COVID-19 treatment researchSarilumabSarilumab (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
 
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Sarilumab for COVID-19: real-time meta analysis of 11 studies

@CovidAnalysis, December 2024, Version 10V10
Post
Share
PDF
Studies
Feedback
https://c19early.org/sarmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ REMAP-CAP Gordon (RCT) 26% 0.74 [0.38-1.43] death 10/45 19/63 Improvement, RR [CI] Treatment Control REMAP-CAP Gordon (RCT) 50% 0.50 [0.21-0.85] death 45 (n) 397 (n) Lescure (DB RCT) 2% 0.98 [0.58-1.68] death 173 (n) 84 (n) Lescure (DB RCT) 3% 0.97 [0.46-2.07] death 18/173 9/84 Lescure (DB RCT) 0% 1.00 [0.47-2.14] death 17/159 9/84 Lescure (DB RCT) -5% 1.05 [0.57-1.91] ICU 114 (n) 56 (n) Lescure (DB RCT) -19% 1.19 [0.53-2.71] ICU 17/114 7/56 Lescure (DB RCT) 10% 0.90 [0.37-2.18] ICU 11/98 7/56 Lescure (DB RCT) 8% 0.92 [0.74-1.15] no improv. 173 (n) 84 (n) Lescure (DB RCT) 12% 0.88 [0.65-1.19] no improv. 173 (n) 84 (n) Lescure (DB RCT) 3% 0.97 [0.71-1.33] no improv. 159 (n) 84 (n) SARTRE Sancho-López (RCT) -3% 1.03 [0.14-7.46] death 2/99 2/102 SARTRE Sancho-López (RCT) 30% 0.70 [0.25-1.91] ICU 7/99 10/102 SARTRE Sancho-López (RCT) -14% 1.14 [0.65-2.00] no recov. 40/99 40/102 SARTRE Sancho-López (RCT) -3% 1.03 [0.48-2.20] no recov. 40/99 40/102 SARTRE Sancho-López (RCT) -3% 1.03 [0.48-2.20] no recov. 40/99 40/102 CORIMUNO-SARI-1 Mariette (RCT) 30% 0.70 [0.31-1.58] death 10/68 16/76 CORIMUNO-SARI-1 Mariette (RCT) 35% 0.65 [0.27-1.59] death 8/68 14/76 CORIMUNO-SARI-1 Mariette (RCT) 32% 0.68 [0.23-2.03] death 6/68 8/76 CORIMUNO-SARI-1 Mariette (RCT) -1% 1.01 [0.58-1.74] no recov. 18/68 20/76 CORIMUNO-SARI-1 Mariette (RCT) -10% 1.10 [0.69-1.74] progression 68 (n) 76 (n) CORIMUNO-SARI-2 Hermine (RCT) 26% 0.74 [0.35-1.58] death 14/48 13/33 SARICOR Merchante (RCT) -35% 1.35 [0.30-6.06] death 39 (n) 39 (n) SARICOR Merchante (RCT) 99% 0.01 [0.00-161] death 0/39 3/39 SARICOR Merchante (RCT) -41% 1.41 [0.31-6.31] death 4/37 3/39 SARICOR Merchante (RCT) -22% 1.22 [0.46-3.23] ventilation 39 (n) 39 (n) SARICOR Merchante (RCT) 22% 0.78 [0.17-3.48] ventilation 3/39 4/39 SARICOR Merchante (RCT) -68% 1.68 [0.47-5.98] ventilation 6/37 4/39 SARICOR Merchante (RCT) 36% 0.64 [0.31-1.32] progression 39 (n) 39 (n) SARICOR Merchante (RCT) 59% 0.41 [0.14-1.18] progression 5/39 11/39 SARICOR Merchante (RCT) 13% 0.87 [0.37-2.06] progression 10/37 11/39 SARCOVID García-Vic.. (RCT) -300% 4.00 [0.21-76.2] death 2/20 0/10 SARCOVID García-Vic.. (RCT) -450% 5.50 [0.31-97.2] ventilation 3/20 0/10 SARCOVID García-Vic.. (RCT) -33% 1.33 [0.73-2.45] 7-point status 20 (n) 10 (n) SARCOVID García-Vic.. (RCT) -50% 1.50 [0.68-3.31] 7-point status 20 (n) 10 (n) Branch-El.. (RCT) -350% 4.50 [1.01-20.1] death 6/20 2/30 Branch-El.. (RCT) -650% 7.50 [0.95-59.5] death/int. 5/20 1/30 Branch-El.. (RCT) -500% 6.00 [0.30-119] ventilation 2/20 0/30 Branch-El.. (RCT) -50% 1.50 [0.34-6.70] ICU 3/20 3/30 REGENERON P3 Sivapala.. (DB RCT) -8% 1.08 [0.83-1.39] death 567 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) -17% 1.17 [0.54-2.56] death 21/137 9/70 REGENERON P3 Sivapala.. (DB RCT) 0% 1.00 [0.73-1.36] death 114/338 59/170 REGENERON P3 Sivapala.. (DB RCT) -32% 1.32 [0.74-2.36] death 40/92 16/46 REGENERON P3 Sivapala.. (DB RCT) 12% 0.88 [0.64-1.21] death 477 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) 36% 0.64 [0.27-1.51] death 12/140 9/70 REGENERON P3 Sivapala.. (DB RCT) 19% 0.81 [0.57-1.14] death 70/242 59/170 REGENERON P3 Sivapala.. (DB RCT) -27% 1.27 [0.71-2.28] death 40/95 16/46 REGENERON P3 Sivapala.. (DB RCT) -6% 1.06 [0.91-1.23] no improv. 567 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) -23% 1.23 [0.67-2.27] no improv. 29/137 12/70 REGENERON P3 Sivapala.. (DB RCT) -6% 1.06 [0.87-1.29] no improv. 164/338 78/170 REGENERON P3 Sivapala.. (DB RCT) -3% 1.03 [0.80-1.33] no improv. 62/92 30/46 REGENERON P3 Sivapala.. (DB RCT) 11% 0.89 [0.76-1.04] no improv. 477 (n) 286 (n) REGENERON P3 Sivapala.. (DB RCT) 0% 1.00 [0.53-1.88] no improv. 24/140 12/70 REGENERON P3 Sivapala.. (DB RCT) 16% 0.84 [0.68-1.03] no improv. 105/242 88/170 REGENERON P3 Sivapala.. (DB RCT) 5% 0.95 [0.73-1.24] no improv. 59/95 30/46 REGENERON P2 Sivapala.. (DB RCT) -7% 1.07 [0.44-2.59] death 180 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -1341% 14.41 [0.87-238] death 9/51 0/25 REGENERON P2 Sivapala.. (DB RCT) 30% 0.70 [0.37-1.35] death 23/88 15/44 REGENERON P2 Sivapala.. (DB RCT) -2% 1.02 [0.45-2.30] death 17/41 9/21 REGENERON P2 Sivapala.. (DB RCT) -22% 1.22 [0.76-1.97] death 187 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -300% 4.00 [0.20-80.3] death 2/50 0/25 REGENERON P2 Sivapala.. (DB RCT) -21% 1.21 [0.66-2.21] death 38/94 15/44 REGENERON P2 Sivapala.. (DB RCT) -15% 1.15 [0.52-2.53] death 20/43 9/21 REGENERON P2 Sivapala.. (DB RCT) -4% 1.04 [0.51-2.15] no improv. 180 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) -292% 3.92 [0.98-15.7] no improv. 16/51 2/25 REGENERON P2 Sivapala.. (DB RCT) 40% 0.60 [0.43-0.84] no improv. 35/88 29/44 REGENERON P2 Sivapala.. (DB RCT) -7% 1.07 [0.66-1.75] no improv. 23/41 11/21 REGENERON P2 Sivapala.. (DB RCT) 12% 0.88 [0.69-1.12] no improv. 187 (n) 90 (n) REGENERON P2 Sivapala.. (DB RCT) 0% 1.00 [0.20-5.09] no improv. 4/50 2/25 REGENERON P2 Sivapala.. (DB RCT) 21% 0.79 [0.59-1.05] no improv. 49/94 29/44 REGENERON P2 Sivapala.. (DB RCT) -15% 1.15 [0.72-1.85] no improv. 26/43 11/21 ESCAPE Mastrorosa (RCT) -30% 1.30 [0.41-4.15] death 10/107 4/52 ESCAPE Mastrorosa (RCT) 7% 0.93 [0.67-1.25] no improv. 121 (n) 55 (n) ESCAPE Mastrorosa (RCT) -8% 1.08 [0.49-2.36] viral+ 17/79 7/35 Sarilumab COVID-19 outcomes c19early.org December 2024 Favors sarilumab Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0